OPKO Health (NASDAQ: OPK) saw its target price raised by Piper Sandler equity researchers from $5.00 to $6.00 in a research report released on Tuesday, reports The Fly. Piper Sandler’s price target suggests a potential upside of 27.12% from the company’s previous close.
Other stock analysts have also recently published research reports on the company. Zacks Investment Research upgraded OPKO Health from a “hold” rating to a “strong-buy” rating and set a target price of $6.00 for the company in a Tuesday, December 28 report. Barrington Research reissued a “buy” rating and published a target price of $6.00 on OPKO Health shares in a research note on Monday, September 27.
OPK traded $0.19 during trading hours on Tuesday, hitting $4.72. The stock had a trading volume of 520,557 shares, compared to an average volume of 4,047,350. The company has a quick ratio of 1.57, a current ratio of 1.97 and a leverage ratio of 0, 11. The stock has a market capitalization of $3.22 billion, a PE ratio of 42.91 and a beta of 1.72. OPKO Health has a 1-year minimum of $3.26 and a 1-year maximum of $6.27. The company’s fifty-day simple moving average is $4.32 and its 200-day simple moving average is $3.94.
OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Thursday, October 28. The biotech company reported EPS of $0.04 for the quarter, beating Thomson Reuters consensus estimate of $0.01 ($0.01) by $0.05. OPKO Health had a return on equity of 4.42% and a net margin of 4.06%. The company posted revenue of $385.80 million in the quarter, compared to analyst estimates of $302.27 million. In the same quarter of the previous year, the company made earnings per share of $0.04. OPKO Health revenue decreased 9.9% year over year. As a group, stock analysts expect OPKO Health to post EPS of 0.04 for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. increased its position in OPKO Health shares by 5.2% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 58,060 shares of the biotech company worth $212,000 after buying 2,854 more shares last quarter. CIBC Asset Management Inc. increased its holdings in OPKO Health by 11.4% during Q3. CIBC Asset Management Inc. now owns 28,189 shares of the biotech company valued at $103,000 after buying 2,883 more shares last quarter. Shell Asset Management Co. increased its holdings in OPKO Health by 5.7% during the second quarter. Shell Asset Management Co. now owns 58,940 shares of the biotech company valued at $239,000 after buying 3,190 additional shares last quarter. Legal & General Group Plc increased its stake in OPKO Health by 1.8% during the second quarter. Legal & General Group Plc now owns 256,870 shares of the biotech company valued at $1,040,000 after buying an additional 4,548 shares last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in OPKO Health by 1.1% during the third quarter. UBS Asset Management Americas Inc. now owns 431,092 shares of the biotech company valued at $1,573,000 after buying 4,577 additional shares last quarter. 26.42% of the shares are currently held by hedge funds and other institutional investors.
About OPKO Health
OPKO Health, Inc, is a biopharmaceutical and diagnostics company, which provides healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes BioReference’s clinical laboratory operations, as well as point-of-care operations.
Recommended Story: Special Purpose Acquisition Corporation (SPAC)
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in OPKO Health right now?
Before you consider OPKO Health, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and OPKO Health wasn’t on the list.
While OPKO Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here